Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.

被引：0
|
作者：
Foltran, Luisa
Bertola, Manuela
Del Conte, Alessandro
Lo Re, Giovanni
Bestetti, Alessandro
Sandri, Paolo
Saracchini, Silvana
机构：
[1] Gen Hosp, Dept Oncol, Pordenone, Italy
[2] Gen Hosp S Maria Angeli, Dept Oncol, Pordenone, Italy
[3] Santa Maria Angeli Hosp, Pordenone, Italy
[4] Santa Maria Angeli Gen Hosp, Pordenone, Italy
[5] S Maria Angeli, Pasiano Di Pordenone, PN, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11576
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11576
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: A single institution experience.
    Ferrarini, Ilaria
    Raoufi, Atefeh
    Bertolini, Ilaria
    Fancelli, Sara
    De Angelis, Carmine
    Diodati, Francesca
    Fontana, Andrea
    Salvadori, Barbara
    Landucci, Elisabetta
    Michelotti, Andrea
    Antonuzzo, Andrea
    Roncella, Silvio
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: a single institution experience
    Ferrarini, I.
    Bertolini, I.
    Fancelli, S.
    De Angelis, C.
    Fontana, A.
    Salvadori, B.
    Landucci, E.
    Michelotti, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 15 - 16
  • [3] Everolimus and exemestane in hormone receptor-positive advanced breast cancer: A comprehensive cancer center's experience.
    Moreira, Ines
    Ferreira, Marta
    Afonso, Ana
    Ferreira, Ana
    Rodrigues, Ana
    Vieira, Claudia
    Oliveira, Cristina
    Savva-Bordalo, Joana
    Dias, Joao
    Cassiano, Maria
    Abreu, Miguel
    Alves, Sara
    Sousa, Susana
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Redana, Stefania
    Papadimitraki, Elisavet
    Okonji, David Odhiambo
    Khabra, Komel
    Thanopoulou, Eirini
    Chiramel, Jaseela
    Papanastasopoulos, Panagiotis
    Wardley, Andrew M.
    Hogg, Martin S.
    Howell, Sacha Jon
    Zucchini, Giorgia
    Kenny, Laura M.
    Ring, Alistair E.
    Johnston, Stephen R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Cost-effectiveness of everolimus plus exemestane in postmenopausal hormone receptor positive metastatic breast cancer
    Zeichner, Simon B.
    Avancha, Kiran Kumar Venkata Raja
    Lopes, Gilberto
    Gluck, Stefan
    Montero, Alberto J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Retrospective Study of the Use of Everolimus/Exemestane in the Treatment of Oestrogen Receptor Positive (ER plus ) Metastatic Breast Cancer (MBC): The Kent Oncology Network Experience
    Ang, J. E.
    Jyothirmayi, R.
    Mithal, N.
    Abson, C.
    Burcombe, R.
    Harper-Wynne, C.
    CLINICAL ONCOLOGY, 2015, 27 (06) : E9 - E9
  • [7] Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 433 - 441
  • [8] Use of alpelisib in the treatment of hormone receptor positive metastatic breast cancer: An institutional experience.
    Tamang, Tsering G. Lama
    Kyung, Daniel
    Eisenbud, Lauren
    Tang, Tianyi
    Parajuli, Ritesh
    Mehta, Rita S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Fulvestrant versus everolimus plus exemestane for patients with metastatic breast cancer resistant to aromatase inhibitors: Clinical experience from real world.
    Li, Yi
    Xie, Yizhao
    Zhao, Yannan
    Hu, Xi-Chun
    Zhang, Jian
    Chen, Shen
    Gong, Chengcheng
    Zhang, Sheng
    Wang, Leiping
    Wang, Biyun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 443 - 443
12345